Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP12: Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn’s disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Joseph Sleiman
Created: Friday, 14 July 2023, 2:22 PM
DOP13: Clinical and endoscopic response to ustekinumab in Crohn’s Disease: Week 16 interim analysis of the STARDUST trial
Year: 2020
Source: ECCO'20 Vienna
Authors: Silvio Danese
Created: Tuesday, 23 June 2020, 5:40 PM
DOP13: Effect of 8 weeks of combined aerobic and resistance exercise on quality of life, muscle strength, aerobic capacity, and disease activity in patients with Inflammatory Bowel Disease; a parallel group randomized clinical trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Alborzi Avanaki, Foroogh
Created: Tuesday, 30 April 2024, 5:03 PM
DOP13: Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Klaudia Farkas
Created: Friday, 14 July 2023, 2:22 PM
DOP14: Identification and validation of a lipidomic signature as a novel diagnostic biomarker of paediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Niklas Nyström
Created: Friday, 14 July 2023, 2:22 PM
DOP14: Proctocolectomy is associated with improved transplant-free survival in patients with primary sclerosing cholangitis: results from a pooled collaborative international study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Mol, Bregje
Created: Tuesday, 30 April 2024, 5:03 PM
DOP15: An evaluation of the exposure-efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s Disease: Pharmacokinetic findings from VISIBLE 2
Year: 2020
Source: ECCO'20 Vienna
Authors: Shashi Adsul
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Thursday, 2 July 2020, 12:11 PM by Eloise Lanaud
DOP15: Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bárbara Morão
Created: Friday, 14 July 2023, 2:22 PM
DOP15: Results of a pragmatic multicentred randomised controlled trial investigating the use of personalised golimumab dosing in Ulcerative Colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis)
Year: 2024
Source: ECCO'24 Stockholm
Authors: Doherty, Glen
Created: Tuesday, 30 April 2024, 5:03 PM
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Alexandra Livanos
Created: Friday, 14 July 2023, 2:22 PM
DOP16: Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
Year: 2024
Source: ECCO'24 Stockholm
Authors: D'Haens, Geert
Created: Tuesday, 30 April 2024, 5:03 PM
DOP16: Transmural healing with vedolizumab in patients with active Crohn’s Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Maria Rosario
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Thursday, 2 July 2020, 12:10 PM by Eloise Lanaud
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Margalida Calafat Sard
Created: Friday, 14 July 2023, 2:22 PM
DOP17: Identification of biomarkers and mechanistic insight for upadacitinib in Ulcerative Colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
Year: 2020
Source: ECCO'20 Vienna
Authors: Séverine Vermeire
Created: Tuesday, 23 June 2020, 5:40 PM
DOP17: Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gros, Beatriz
Created: Tuesday, 30 April 2024, 5:03 PM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn’s Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Anne Thomann
Created: Friday, 14 July 2023, 2:22 PM
DOP18: Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Peyrin-Biroulet, Laurent
Created: Tuesday, 30 April 2024, 5:03 PM
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jae Jun Park
Created: Tuesday, 23 June 2020, 5:40 PM
DOP19: High dimensional profiling of IL-23-responsive cells revealed molecular signatures that predict response to anti-IL-23 therapy in patients with Crohn’s Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Deepak, Parakkal
Created: Tuesday, 30 April 2024, 5:03 PM
DOP19: Incidence and initial disease presentation of inflammatory bowel diseases in Denmark: findings from a Copenhagen IBD Inception Cohort Study (IBD Prognosis Study)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mohamed Attauabi
Created: Friday, 14 July 2023, 2:22 PM